Gilead Sciences, Inc. (Nasdaq: GILD), the Foster City, California-based biopharmaceutical company, announced on October 19, 2026, that it will present 28 research findings, including two oral presentations, at IDWeek 2026 in Washington, DC, from October 21 through October 24. The programme examines new clinical and real-world evidence involving Bixlenvo, its recently approved once-daily HIV treatment combining bictegravir and lenacapavir, and Yeztugo, its twice-yearly injectable medicine for HIV pre-exposure prophylaxis. Gilead will also present final Phase 1b findings for GS-1179, an investigational long-acting oral medicine being developed to suppress recurrent genital herpes. The presentations reflect an effort to extend established antiviral treatment beyond conventional daily regimens while addressing persistent gaps in access and adherence.
The research arrives less than two months after the FDA approved Bixlenvo for adults with HIV whose viral replication is already suppressed on a stable antiretroviral regimen. New analyses from the Phase 3 ARTISTRY-1 and ARTISTRY-2 studies will examine treatment outcomes in patients with dyslipidemia, hypertension, diabetes and renal impairment. Separately, Gilead will present the first nine months of United States adoption data for Yeztugo following its June 2025 approval, helping establish how twice-yearly HIV prevention is being introduced into routine practice.
The company’s emerging antiviral programme includes GS-1179, previously developed as ABI-1179 through a collaboration with Assembly Biosciences. Earlier Phase 1b findings demonstrated a 98% reduction in HSV-2 viral shedding compared with placebo at a studied once-weekly oral dose, providing evidence of substantial antiviral activity. However, Gilead’s October announcement does not disclose the full updated efficacy and safety results scheduled for IDWeek, and GS-1179 remains investigational.
The scientific programme combines findings from approved products, observational studies and early-stage drug development. These different evidence types must be interpreted separately because successful HIV suppression, prevention uptake and reduction in herpes viral shedding address distinct clinical objectives. The next question for Gilead is whether the findings can improve treatment selection and real-world implementation while advancing new antiviral medicines toward larger trials.
What will the ARTISTRY-1 and ARTISTRY-2 analyses reveal about Bixlenvo?
Bixlenvo combines bictegravir 75 mg with lenacapavir 50 mg in a single tablet taken once daily. The FDA approved the medicine on August 27, 2026, for adults with HIV-1 who have maintained virological suppression on an existing regimen and have no known or suspected resistance to its components. The treatment is intended to replace an established suppressive regimen rather than serve as an approved initial treatment for people with uncontrolled HIV infection.
The ARTISTRY-1 and ARTISTRY-2 Phase 3 trials established that switching to the combination could maintain viral suppression comparably to the treatment regimens used in the respective control groups. The studies enrolled different populations, including people receiving complex multitablet regimens and those taking Biktarvy. Gilead’s new IDWeek analyses focus on patients with additional medical conditions that may complicate antiretroviral treatment.
These comorbidities are clinically relevant because people living with HIV are increasingly reaching older ages and may require medicines for hypertension, diabetes, abnormal lipid levels and kidney disease. Treatment simplification can reduce pill burden, but the replacement regimen must also remain suitable alongside other prescribed medicines. Renal function, drug interactions and metabolic characteristics can therefore influence treatment decisions.
The forthcoming analyses may provide more detail about maintaining viral suppression within these patient groups. However, the October announcement does not disclose the numerical results of the new subgroup investigations. Their interpretation will depend on sample sizes, baseline characteristics and whether treatment effects are consistent across the evaluated populations.
How effective was Bixlenvo in the original Phase 3 studies?
The pivotal ARTISTRY-1 trial included adults whose HIV remained suppressed on complex antiretroviral regimens. Participants were randomized either to switch to Bixlenvo or continue their established treatment. The study enrolled 371 patients in the Bixlenvo group and 186 in the comparator group for the principal Week 48 efficacy analysis.
According to the FDA-approved prescribing information, 96% of Bixlenvo recipients had HIV-1 RNA below 50 copies per milliliter at Week 48, compared with 94% continuing their baseline regimen. Virological failure, defined by HIV-1 RNA at or above 50 copies per milliliter under the trial’s reporting method, occurred in approximately 1% of each group. The results supported noninferiority in maintaining suppression.
ARTISTRY-2 compared switching to Bixlenvo with continuing Biktarvy. At Week 48, 93% of patients receiving Bixlenvo maintained HIV-1 RNA below 50 copies per milliliter, compared with 91% remaining on Biktarvy. Again, approximately 1% in each group met the virological failure threshold.
These findings support the efficacy of Bixlenvo as a switch treatment in appropriately selected, already suppressed adults. However, they do not establish that the combination cures HIV or is suitable for patients with untreated infection or resistance to its components. The new IDWeek presentations will add more focused information about patients with particular medical characteristics rather than replace the original pivotal efficacy results.
The initial ARTISTRY data also identified differences in some metabolic and patient-reported outcomes. These observations may help guide treatment selection, but subgroup findings require careful interpretation because individual comorbidities can influence laboratory measurements and medication use independently of HIV therapy.
Why is treatment simplification important for older people living with HIV?
The ARTISTRY-1 study enrolled a particularly treatment-experienced population, with a median age of 60 years. Participants had received HIV therapy for a median of approximately 28 years and were taking between two and 11 antiretroviral tablets daily at baseline. Around 40% took antiretroviral medication more than once per day.
The trial also included substantial historical drug resistance. Gilead reported that approximately 67% had prior nucleoside reverse transcriptase inhibitor resistance, while many were receiving complex regimens because earlier treatments were no longer suitable. Such patients can face a different set of clinical challenges from adults who have achieved suppression using a standard initial regimen.
Reducing the number of tablets may improve convenience and potentially support adherence. However, successful simplification must preserve adequate antiviral activity against the patient’s virus. Clinicians need to consider historical resistance records even when current viral load testing shows suppression.
Bixlenvo uses two antiviral mechanisms. Bictegravir inhibits HIV integrase, while lenacapavir interferes with the viral capsid at multiple stages of the replication cycle. The combination provides a treatment option for selected patients who cannot easily move to existing single-tablet alternatives.
Its approved use also requires an initial two-day oral lenacapavir loading regimen using Sunlenca tablets alongside Bixlenvo. Maintenance treatment then continues with one Bixlenvo tablet daily. The initiation requirement matters because simplification is not achieved by simply replacing the previous regimen with one tablet without following the prescribed starting schedule.
What will the new data show about kidney function and metabolic conditions?
The IDWeek programme includes an ARTISTRY-1 analysis of participants with renal impairment and another examining safety in patients with dyslipidemia, hypertension and diabetes. ARTISTRY-2 will contribute additional metabolic and safety findings among people with selected baseline conditions. These analyses address the characteristics of patients commonly encountered in long-term HIV care.
Kidney impairment can affect the selection and dosing of certain medicines. Some antiretroviral regimens contain components that require particular attention to renal function or other clinical factors. A switch regimen may therefore be useful for eligible patients, but its suitability cannot be inferred solely from the presence of kidney disease.
Metabolic outcomes also matter because people living with HIV may have cardiovascular risk factors requiring long-term management. Changes in cholesterol, blood glucose or weight may influence treatment preferences, especially when patients have been receiving antiretroviral therapy for many years. However, such changes must be interpreted in relation to baseline medications and the comparator regimen.
In earlier ARTISTRY-1 results, switching to Bixlenvo was associated with improvements in some fasting lipid measurements and greater patient-reported treatment satisfaction. The new presentations may help clarify whether similar patterns occur among patients who already have particular metabolic conditions. The company has not disclosed new subgroup effect sizes in its October preview.
The findings should therefore be described as forthcoming analyses of an approved product, not as evidence of a newly established renal or metabolic indication.
What will the first nine months of Yeztugo use reveal about HIV prevention?
Yeztugo contains lenacapavir and was approved by the FDA on June 18, 2025, as a twice-yearly injectable option for HIV pre-exposure prophylaxis. The approved prevention indication applies to eligible adults and adolescents at risk of sexually acquired HIV. Gilead will present real-world adoption patterns from June 2025 through March 2026, covering the early period following its United States introduction.
The presentation is important because the effectiveness demonstrated in clinical trials does not automatically establish how quickly a medicine will be adopted outside research settings. Preventive treatment depends on individuals being able to access services, obtain coverage and complete the required administration schedule. These practical factors can influence how much of the clinical potential translates into population-level benefit.
The IDWeek programme includes an oral presentation examining early adoption, as well as research addressing provider education, patient access and linkage to HIV prevention services. Additional studies will consider the economic and public health effects of introducing twice-yearly PrEP into communities with unmet prevention needs. These analyses may help identify barriers that cannot be addressed simply by reducing dosing frequency.
However, the October announcement does not disclose a definitive count of new Yeztugo users or a national initiation rate for the nine-month period. Any conclusions about adoption must await the actual presentation data and their denominators. Early uptake also should not be confused with demonstrated long-term retention or adherence over several years.
The research may help Gilead and healthcare organizations understand how to expand use, but it does not independently establish that the prevention programme has reduced HIV incidence at a population level.
How do the PURPOSE studies inform lenacapavir’s prevention strategy?
Gilead’s lenacapavir prevention programme includes the PURPOSE 1 and PURPOSE 2 trials, which provided pivotal evidence supporting the original regulatory authorization. These studies investigated the ability of twice-yearly lenacapavir injections to reduce HIV acquisition in different populations. Their results established a substantial clinical basis for the medicine’s prevention role.
The IDWeek programme includes further analyses involving sexually transmitted infections, hepatitis B incidence and prevention-related behavior among PURPOSE participants. These findings can inform the broader context of preventive care because people receiving HIV PrEP may also require screening and management for other infections. However, lenacapavir does not provide comprehensive protection against all sexually transmitted infections.
Another poster will describe baseline characteristics and substance use among people who inject drugs in HPTN 103, also known as PURPOSE 4. This Phase 2 research addresses a population with important prevention needs but different patterns of potential HIV exposure from those represented in the original sexually acquired HIV prevention indication. Its findings should not be presented as an already approved new indication.
The company is also investigating potential economic benefits from expanding twice-yearly PrEP. Such estimates are modeling exercises that depend on assumptions concerning uptake, treatment costs and changes in HIV incidence. They should be distinguished from measured clinical outcomes.
The broader programme reflects a shift from establishing that lenacapavir can prevent HIV acquisition in clinical trials toward determining how preventive services can reach populations with different access needs. Success will depend on the healthcare systems and support structures surrounding the medicine, not only on its pharmacological characteristics.
Why is GS-1179 an important addition to Gilead’s antiviral research?
GS-1179 is an investigational oral helicase-primase inhibitor being developed for recurrent genital herpes caused by herpes simplex virus infection. The candidate was previously known as ABI-1179 and originated through research conducted by Assembly Biosciences. Gilead obtained rights to the programme under its collaboration with Assembly.
Herpes simplex virus establishes persistent infection and can reactivate periodically, causing recurrent lesions and viral shedding. Existing medicines such as acyclovir and valacyclovir inhibit viral DNA replication through established nucleoside-based mechanisms. They can reduce outbreaks and shedding but do not eliminate latent infection.
Helicase-primase inhibitors target a different part of the viral replication machinery. The helicase-primase complex helps separate and prepare viral DNA for replication, making it a potentially valuable therapeutic target. A medicine acting through this mechanism could provide an additional option, particularly if it supports convenient long-acting dosing.
Assembly Biosciences reported earlier Phase 1b findings from GS-1179 in December 2025. At the studied 50 mg once-weekly dose, the candidate reduced HSV-2 shedding by 98% compared with placebo over a 29-day evaluation period. It also produced a reported 91% reduction in the rate of virologically confirmed genital lesions.
These results support continued investigation but do not establish clinical superiority over approved herpes medicines. The original population and follow-up were limited, and the complete development programme must assess safety, resistance, recurrence patterns and longer-term treatment outcomes.
What safety and efficacy questions remain for the herpes programme?
Gilead’s IDWeek presentations will include final Phase 1b efficacy and virological analyses of GS-1179, together with additional safety findings. The October announcement does not provide the complete updated numbers. The previously reported reductions in shedding and lesions therefore remain the relevant published clinical observations until the new presentations are available.
Viral shedding is an important endpoint because herpes simplex virus can be released from infected tissue even when visible lesions are absent. Reducing shedding may affect the biological conditions associated with viral transmission. However, a lower shedding rate does not automatically establish a quantified reduction in transmission to partners.
The earlier study also reported generally favorable tolerability, with most adverse events classified as mild or moderate. However, early trials involving relatively small populations cannot reliably identify uncommon or delayed adverse reactions. Repeat dosing over longer periods will be particularly important for a treatment intended to suppress recurrent disease.
Another question is whether weekly oral administration produces more consistent suppression than existing regimens in routine practice. That comparison requires an appropriately designed trial involving relevant treatment standards. The convenience of a longer interval is potentially valuable but cannot substitute for confirmed efficacy and safety.
The forthcoming findings may help determine the appropriate next development step. GS-1179 remains investigational and is not an approved treatment for genital herpes.
What does the ACCELERATE study examine about restarting HIV treatment?
Another major component of Gilead’s IDWeek programme concerns people who have interrupted antiretroviral treatment and are returning to care. The Phase 4 ACCELERATE implementation study evaluates rapid restarting of treatment using Biktarvy within a multisite healthcare setting. The study will be presented during one of the conference’s oral sessions.
Treatment interruption can allow viral replication to resume, increasing health risks and potentially creating further challenges for long-term disease management. Returning to effective therapy is therefore an important clinical objective. However, individuals who have been out of care may face barriers involving insurance, transportation, stigma or other circumstances that affect continuity.
Implementation research examines how a treatment strategy works when delivered through ordinary healthcare services. Unlike a conventional pivotal drug trial, it may focus on practical outcomes such as time to restarting therapy, retention in care and feasibility across participating clinics. These measures are important for translating established HIV treatment efficacy into sustained patient benefit.
The October announcement does not disclose the ACCELERATE results. It would therefore be premature to state how many patients successfully restarted therapy or how quickly viral suppression was achieved. The findings may nevertheless provide information relevant to healthcare organizations seeking to improve continuity of HIV care.
What will determine the importance of Gilead’s IDWeek findings?
The conference programme illustrates three different stages of antiviral development. Bixlenvo is an approved HIV treatment undergoing additional evaluation in medically complex populations. Yeztugo is an approved prevention medicine whose practical implementation is being studied, while GS-1179 remains an investigational candidate requiring further clinical development.
Their commercial and clinical implications are therefore different. Bixlenvo’s ongoing analyses may help physicians understand which suppressed patients can benefit from treatment simplification. Yeztugo’s real-world research may identify access barriers and opportunities for wider preventive use, while GS-1179 could eventually support expansion into another antiviral treatment category.
The programme also reinforces lenacapavir’s role across multiple strategies. The medicine is used in HIV prevention and treatment, while Gilead continues investigating alternative combinations and administration schedules. However, a shared active ingredient does not mean the products have the same dosing, indications or safety requirements.
The company has announced 28 presentations but has not yet disclosed complete new results from the scheduled conference sessions. Their ultimate value will depend on the quality of the underlying data, the populations studied and whether they lead to changes in clinical practice.
Gilead’s October 2026 programme demonstrates the breadth of its antiviral research, ranging from simplifying established HIV therapy to evaluating new approaches for persistent herpes infection. The strongest available evidence comes from already completed clinical studies supporting approved products and from early GS-1179 antiviral activity.
The next step is translating those findings into practical benefits for patients. More detailed subgroup evidence, real-world prevention outcomes and longer-term herpes data will help clarify where the company can improve treatment access, convenience and disease management without overstating what its current research has established.
